1519 results about "Stomach cancer" patented technology

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

The invention discloses a big data deep learning-based stomach cancer pathological diagnosis support system and method. The system comprises an image data obtaining unit, an image data labeling unit, an image database construction unit, a convolutional neural network (CNN) construction unit and a convolutional neural network training unit, wherein the image data obtaining unit is used for obtaining stomach normal tissue slice images and pathological slice images of definite stomach cancer cases as input image data; the image data labeling unit is used for labeling the input image data; the image database construction unit is used for classifying and arranging the labeled image data provided by the image data labeling unit so as to construct a pathological image database; the convolutional neural network (CNN) construction unit is used for constructing a first convolutional neural network model; and the convolutional neural network training unit is used for obtaining an ideal convolutional neural network model. Through the stomach cancer pathological diagnosis support system and method, accurate and efficient intelligent slice reading can be realized so as to assistant the clinical stomach cancer pathological diagnosis work and improve the correctness, work efficiency and work persistent state.

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with stomach cancer. The biological compositions can be used to retard the growth of stomach cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

The present invention relates to a RUNX3 gene showing anti-tumor activity which is essentially involved in TGF-β dependent-programmed cell death (apoptosis) and use thereof. In addition, the present invention finds that the RUNX3 gene expression is suppressed in the various gastric cancer and lung cancer cell lines. The suppression of the RUNX3 gene expression is due to hyper-methylation of CpG island located around RUNX3 exon (1). The RUNX3 gene and its gene product of the present invention can be used effectively for the development of anti-cancer agents. CpG island around RUNX3 exon (1) could also be used not only for the development of anti-cancer agents which regulate the abnormal DNA methylation and there by induce RUNX3 expression but also for the development of methods for cancer diagnosis by measuring the abnormal DNA methylation.

Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

The invention discloses a traditional Chinese medicine preparation for treating cancer, which is prepared by 103 types of bulk drugs such as solidago decurrens, Chinese sage herb, hypericum japonicumand the like. A preparation method of the traditional Chinese medicine preparation comprises the following steps: preparing the bulk drugs into water extract by a conventional method; using the prepared water extract for preparing oral solution by a traditional method; drying the obtained water extraction, then conducting grinding and sieving; taking the throughs for extracting powder, and using the extracted powder for preparing tablets, granules, electuaries or capsules by a traditional method. The preparation method also can be as follows: sieving out the dust of the bulk drugs, conductinggrinding and sieving, taking the throughs, conducting disinfection and sterilization to obtain raw powder, and using the raw powder for preparing tablets, granules, electuaries or capsules by a traditional method. With drugs mixed rationally, the traditional Chinese medicine preparation addresses both the symptoms and root causes of cancer. The bulk drugs are frequently-used common Chinese drugs,have low preparation cost and small side effect, and can effectively enhance own immunity, attack pathogen while do not damage body. The traditional Chinese medicine preparation can cure various typesof cancer, particularly lung cancer, stomach cancer, liver cancer, esophageal cancer, pancreatic cancer, cervical cancer and breast cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.

Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

The invention discloses a latex enhanced turbidimetric immunoassay kit for diagnosing gastric diseases or gastric cancer, a preparation method thereof and application. Components of the kit include diluent, blank solution and a latex reagent of an antibody of pepsinogen I or an antibody of pepsinogen II and can further include a calibrator and quality control serum. The latex reagent contains nanoparticles coupled with the antibody of the pepsinogen I or the antibody of the pepsinogen II, and the particle sizes of the nanoparticles are different. The examination sensitivity cannot meet requirements when latex with the single particle size lower than 100nm is used for examination, the linear range is small when latex with the single particle size of about 200nm is used for examination, and accordingly the examination sensitivity and the linear range cannot meet requirements when latex with the single particle size is used for examination. After composite latex of the kit is used for marking, the examination sensitivity can be improved, the linear examination range can be broadened, and the latex enhanced turbidimetric immunoassay kit has the advantages of fast examination, high sensitivity and specificity, good accuracy and the like in terms of gastric disease or gastric cancer examination.

The invention provides a conditioning and making method and a high-efficiency even drying method for a small trash fish marine product, belonging to the technical fields of food conditioning and aquatic product processing. The main process of the invention comprises the following steps of: removing three parts (fish scale, fish head and viscera) of a fresh or iced and fresh small trash fish marine product, washing the small trash fish marine product with clear water, slicing the small trash fish marine product into fish chips with the length of 6-10cm, deodorizing preprocessed fish meat for 4hours with compound rinsing fluid, then carrying out ultrasonic assisted vacuum impregnation conditioning (pickling and seasoning), secondary rinsing, draining, medium-short wave infrared drying pre-dehydrating, pulse spraying negative pressure microwave drying, packaging and sterilizing, thus the small trash fish dried fish prepared food product is obtained. The small trash fish marine product disclosed by the invention has good colour, fragrance and taste, beautiful appearance, low moisture content and complete nutrition, is a high-protein and low-fat food, is beneficial to reducing cholesterol and preventing cardiovascular and cerebrovascular diseases after being eaten for a long time, can be used for adjuvant therapy on leukaemia, stomach cancer and the like and is a high-quality leisure food for both the old and the young.

The present invention relates to one kind of Chinese medicine preparation for curing gastropathy radically. The Chinese medicine preparation is prepared with 29 kinds of Chinese medicinal materials, including astragalus root, corydalis tuber, cuttlebone, chicken's gizzard membrane, white atractylodes rhizome, etc. It has obvious curative effect on various kinds of chronic gastritis, antrum gastritis, digestive track ulcer, etc and no toxic side effect, and can prevent gastric cancer and gastric mucosa pathology.

This invention is related to a method for the detection of early or pre-cancer using DNA isolated from blood and body fluids. This invention provides an improved methylation-based PCR assay, a panel of methylated-based cancer-related gene markers for the detection of general cancer and a panel of demethylation-based tissue- or cell-specific gene markers for discriminating different type of cancer detected from blood samples. This method couples a sequential cancer-related gene marker detection and tissue or cell-specific gene marker assay and is particularly useful as a simultaneous screening test for following type of cancer: lung, breast, ovarian, colon, stomach, prostatic, pancreatic and liver cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.

The present invention relates to a six-item tumor labeling material micro array (Array)-enzyme linked immunosorbent assay (ELISA) detection kit, in particular to a six-item tumor labeling material micro array (Array)-enzyme linked immunosorbent assay (ELISA) detection kit which is used for detecting the characteristic protein which has an indicating function to the liver cancer, lung cancer, colorectal cancer, stomach cancer, pancreatic cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and other tumor diseases.

The present invention is an orally-administrable composition for preventing and treating Helicobacter pylori-associated stomach gastritis and ulcers, and for preventing Helicobacter pylori-associated stomach cancer. The invention is a herb or herb extract containing an anti-H. pylori activity. The invention further includes methods for making and methods for using the invention.

The invention discloses a method for labeling and complementing gastric cancer pathological slices based on pseudo-label iterative annotation. The method comprises the steps that 1), pseudo-label samples are produced by using the original positive samples and the original negative samples of the gastric cancer pathological slices; 2), image segmentation is conducted on the pseudo-label samples, and the pseudo-label samples are used as training images and transmitted to U-Net to be trained; 3), data augmentation is conducted on the original positive samples and transmitted to the trained U-Netin step 2) to be tested, reduction is conducted based on an augmentation manner, and finally weighted averaging is conducted on all images and the images are integrated to obtain a gastric diseased probability graph; 4), the parts of which the gastric cancer diseased probability is higher than a threshold value are screened out, extracted and spliced to the original negative samples to generate the pseudo-label samples of the next iteration; iteration is constantly conducted on the above processes to finally obtain the gastric cancer pathological slices which are completely annotated. By meansof the method, human resources needed to be consumed by slice annotation are greatly reduced, the quantity and quality of a training data set are improved, and probability is provided for training amore accurate deep learning model.

A RNA nanoparticle is disclosed. According to base pairing rules, a particle is formed from a chain RNA, b chain RNA and c chain RNA, wherein sequence of the a chain RNA is SEQ ID No.1; sequence of the b chain RNA is SEQ ID No.2; and sequence of the c chain RNA is SEQ ID No.3. It shows through experimental verification at the cellular and animal level that the RNA nanoparticle provided by the invention has good biosecurity and excellent gene interference effect and specificity, can effectively inhibit growth of gastric cancer cell lines and transplant subcutaneous sarcoma and can be applied in prevention, cure and diagnosis of stomach cancer.

The invention discloses a stomach cancer prognostic marker screening and classifying method based on a gene expression profile. The stomach cancer prognostic marker screening and classifying method comprises that a gene the expression of which is changed is screened out from data of the gene expression profile Cox proportional hazard model analysis is established aiming at the screened gene, a gene which has statistical significance is selected as a seed gene, a maximum likelihood model is constructed by means of clinical follow-up information data of the patient to screen out prognosis key genes, then the risk coefficient of each prognosis key gene in the patient is calculated, classification and statistic verification are carried out in dependence on the number of prognosis key genes of the patient, and an optimal classification mode is selected. According to the invention, dimensionality of high-dimension miscellaneous gene expression profile data can be effectively reduced, several key genes which can be applied to clinical detection easily are screened out from tens of thousands of genes, survival and the recurrence risk of the patient are predicted by means of the expression case of the several key genes.

The present invention provides a paris total saponin extract for resisting tumor metastasis and a pharmaceutical preparation thereof. The pharmaceutical preparation is composed of paris total saponin extract as the active component and medicinal auxiliary materials; wherein, the weight percentage of paris total saponin extract in the total weight of the pharmaceutical preparation is 60 to 98 percent. The paris total saponin extract for resisting tumor metastasis and the pharmaceutical preparation provided by the present invention have good inhabitation on the metastasis of animal transplanted tumor cells, demonstrated in (1) significant anti-metastasis function for inbred mice and nude mice metastasis model of vaccinated mouse lung adenocarcinoma, human lung cancer, human gastric cancer, human intestinal cancer, human liver cancer and other tumor strains; (2) significant effect on relative albumen metastasis; (3) significant effect on relative gene metastasis and no obvious toxicity on major viscera. In addition, the main active component of the pharmaceutical preparation is a Chinese medicine extract, so compared with chemical drugs, the present invention has the advantage of small toxicity.

The invention discloses a CRISPR-Cas9 system for knocking out the gene GRIN2D and its application. The CRISPR-Cas9 system comprises Cas9 and gRNA specifically targeting to the gene GRIN2D. The invention also discloses application of the CRISPR-Cas9 system to preparation of drugs used for treating cancer and application of the gene GRIN2D to diagnostic kits and medicines used for precise treatmentof stomach cancer and other tumors. In virtue of a clinical sample tissue chip of stomach cancer, the gene GRIN2D is proved to be increased in expression in stomach cancer tissue and be related to prognosis according to immunohistochemical results. The CRISPR-Cas9 system provided by the invention can highly efficiently knock out the highly-expressed gene GRIN2D in stomach cancer and inhibit the proliferation and migration / invasion of gastric cancer cells, and is simple to operate and high in knockout efficiency. The CRISPR-Cas9 system is expected to be applied to diagnosis and treatment of stomach cancer and other tumors with over-expressed GRIN2D. The CRISPR-Cas9 system is applicable to a plurality of tumors with abnormal expression of GRIN2D.

This invention relates to methods and compositions for determining the prognosis of cancer in a patient, particularly for gastrointestinal cancer, such as gastric or colorectal cancer. Specifically, this invention relates to the use of genetic markers for the prediction of the prognosis of cancer, such as gastric or colorectal cancer, based on cell proliferation signatures. In various aspects, the invention relates to a method of predicting the likelihood of long-term survival of a cancer patient, a method of determining a treatment regime for a cancer patient, a method of preparing a personalized genomics profile for a cancer patient, among other methods as well as kits and devices for carrying out these methods.

The invention discloses an enzyme linked immunosorbent assay kit for combined diagnosis of the gastrosis or evaluation of gastric cancer risks and a preparation method thereof. The kit comprises a micropore plate coated with an antibody against a pepsin antigen I or an antibody against a pepsin antigen II, an enzyme labeled antibody, a color-developing agent, a stop solution and a concentrated cleaning solution, wherein the pepsin antigen I or the pepsin antigen II is a natural protein obtained from extraction of human gastric mucosa tissue. The kit disclosed by the invention adopts a mouse immunized with pepsinogen I and pepsinogen II which are separated from human gastric mucosa to prepare immunogen of a monoclonal antibody, the used standard sample also adopts the pepsin antigen I or the pepsin antigen II separated from the human gastric mucosa, thereby the defects caused by adopting different structures of animal pepsinogen and human pepsinogen are filled. The kit can be used for accurately diagnosing the gastrosis or early gastric cancer and has the advantages of high sensitivity, strong specificity, good accuracy and the like.

The invention discloses an LncRNA combination for detecting a prognosis condition of stomach cancer and a kit containing the combination. According to the invention, a fluorescent quantitation PCR or digital PCR technique is adopted to identify the difference change of a set of specific LncRNA expression quantity in a stomach cancer patient sample (tissue, plasma, serum, gastric juice, and the like) and a corresponding paracancerous sample or normal sample and to early and accurately evaluate the risk of stomach cancer relapse or transfer. The kit disclosed by the invention provides a biomarker LncRNA combination for detecting the prognosis condition of stomach cancer, a primer for detecting the LncRNA contained in the combination and a related reagent, so that the kit is capable of effectively increasing the detection efficiency and accuracy for the stomach cancer prognosis relapse or transfer. The invention adopts a set of prognosis transfer related LncRNA combination for avoiding the defect of great increasing of the fault diagnosis rate and missed diagnosis rate of the stomach cancer diagnosis caused by lower sensitivity and specificity resulted from a detection index LncRNA served as a tumor marker kit.

The invention relates to nitrogen-atom-containing arteannuin dimers disclosed as Formula (1) and pharmaceutically acceptable salts thereof, wherein X is NR, NR(CH2)nNR or a formula disclosed in the specification; R is H or C14 alkyl group; Y and Z are respectively (CH2)m, (CH2)n(OCH2CH2)m, OC(CH2)nCO or COAr; Ar is phenyl group, naphthyl group or heterocyclic group; N is a 2-8 whole number, and mis a 1-11 whole number; and the heterocyclic group is quinary or sexenary, and contains 1-2 heteroatoms selected from N, O and S. The invention also provides a preparation method of the nitrogen-atom-containing arteannuin dimers, a pharmaceutical composition of the nitrogen-atom-containing arteannuin dimers, and application of the nitrogen-atom-containing arteannuin dimers in preparing drugs for treating cancers, especially endometrial carcinoma, oophoroma, cervical carcinoma, breast cancer, colon cancer, lung cancer, prostatic cancer, liver cancer and / or stomach cancer.

The invention discloses a traditional Chinese medicine composition for treating tumours and a preparation method thereof. The traditional Chinese medicine composition contains a bufogenin extract anda medicinal carrier, wherein the bufogenin extract is prepared by the purification of a silica gel column after being extracted by a toad venom medicinal material, the total content is not below 92%,and then the traditional Chinese medicine composition is prepared by dissolution, filtration, encapsulation and sterilization and can be further prepared into a liquor for injection or freeze-drying powder injection. The traditional Chinese medicine composition has a favorable anticancer action for lung cancer, liver cancer, mammary cancer, stomach cancer, colonic cancer and the like, can increaseleucocyte and has less side effect.

A magnetic nanoparticle-human liver cancer resistant monoclonal antibody Hab18 or its fragment Hab18F (abí»)2 or Hab18Fab as the target medicine in the form of injection for preventing and treating the liver cancer, stomach cancer and intestinal cancer by magneto-thermal therapy is proportionally prepared from magnetic nanoparticles and said antibody. Under the action of magnetic field, it can generate the heat 10-7000 W / gFe to kill cancer cells.

The invention belongs to the field of medicines, relates to anti-tumor medicines, and in particular relates to anti-tumor medicines in double-aryl urea structures based on indazole, indole, azaindazole or azaindole. The structural formulae of the anti-tumor medicines are shown in formula (Ia) and formula (Ib), wherein Z is N atom or C atom; W is O; M is O, S, N or CH; n is 1 or 2; Y and R are halogen atoms, H, R1, CF3, OCF3, OH, OR2, OCOR3, NH2, NHR4, NR52, NHCOR6, carboxyl group, ester group, cyano group, mercapto group, alkyl sulphanyl, sulfuryl, sulfoxide, sulfonic group, sulfamate, sulfonamide, ketonic group, aldehyde group, nitro group or nitroso group. Pharmacodynamic experiments prove that the medicines have good anti-tumor effects on human lung cancer, human kidney cancer, human colon cancer, human liver cancer, human gastric cancer, human breast cancer, melanoma and the like.